NCT06122948View on ClinicalTrials.gov

Effect of Intranasal Midazolam Versus Ketamine Midazolam Combination as a Premedication on the Occurrence of Postoperative Respiratory Adverse Events

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

November 4, 2023

Primary Completion Date

October 10, 2024

Study Completion Date

October 10, 2024

Conditions
TonsillectomyAdenoidectomyDrug-Related Side Effects and Adverse Reaction
Interventions
DRUG

The midazolam group

The midazolam group will receive intranasal midazolam (0.1 mg/kg)

DRUG

The midazolam ketamine group

the midazolam ketamine group will receive intranasal midazolam (0.1mg/kg) and ketamine (3mg/kg)

Trial Locations (1)

11559

Cairo university hospitals, kasralainy, Cairo

All Listed Sponsors
lead

Kasr El Aini Hospital

OTHER

NCT06122948 - Effect of Intranasal Midazolam Versus Ketamine Midazolam Combination as a Premedication on the Occurrence of Postoperative Respiratory Adverse Events | Biotech Hunter | Biotech Hunter